INSPRA (eplerenone) Product Monograph. Page 2 of Table of This leaflet is a summary and will not tell you everything about INSPRA. X. Package leaflet: Information for the patient. Eplerenone 25 mg film-coated tablets. Eplerenone 50 mg film-coated tablets. Eplerenone. Read all of this leaflet . Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Inspra (eplerenone).
|Published (Last):||18 August 2007|
|PDF File Size:||14.23 Mb|
|ePub File Size:||18.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
The effect of eplerenone on BP was analyzed in 1, patients who met the criteria stated in the method section. The incidence of adverse drug reactions was 2. It is the active metabolite of the drug prednisone and is used especially in patients with liver failure, as these individuals are unable to metabolize prednisone into active prednisolone. Two fixed-dose, placebo-controlled, 8- to week monotherapy studies in patients with baseline diastolic blood pressures of 95 to mm Hg were conducted to assess the antihypertensive effect of Eplerenone.
Repeat dose administration of Eplerenone to rats increases the hepatic conjugation and clearance of thyroxin, which results in increased levels of TSH by a compensatory mechanism. Subscribe to receive email notifications whenever new articles are published.
The pharmacokinetics of Eplerenone mg has been investigated in patients with moderate Child-Pugh Class B hepatic impairment and compared with normal subjects.
This study was funded by Pfizer Japan Inc. The difference in the frequency of ADRs between the PMS and the clinical trials is attributable to differences in study design, as a PMS is an observational study and the clinical trials were interventional studies. The safety and efficacy of Eplerenone has been evaluated in clinical studies of hypertensive patients.
Patients treated with Eplerenone 50 mg to mg daily experienced significant decreases in sitting systolic and diastolic blood pressure at trough with differences from placebo of 6 to 13 mm Hg systolic and 3 to 7 mm Hg diastolic.
Abstract Prospective postmarketing surveillance of Selara eplerenonea selective mineralocorticoid receptor antagonist, was performed to confirm its safety and efficacy for hypertension treatment in Japan.
Many patients will require more than one drug to achieve blood pressure goals. Clinicians should pay careful attention to the contraindications listed on the package insert when prescribing drugs and conducting regular monitoring of serum potassium levels. The mean duration of eplerenone treatment was days, and the median was Retention of serum potassium is known to occur more frequently in patients with renal impairment. The incidence of adverse drug reactions classified according to the concomitant antihypertensive medication is presented in the Supplementary Material Table S2 to S9.
Eplerenone has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion.
Eplerenone – FDA prescribing information, side effects and uses
The physicians in charge were encouraged to consult the Guidelines for the Management of Hypertension to determine the severity of hypertension in a comprehensive manner. Eplerenone Rating 4 User Reviews 8. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Very little change in the serum potassium level was observed in patients with serum potassium levels of over 4. Page 2 of 20 full prescribing information 1 indications and usage 1.
The reasons for discontinuation were AEs Hypertension is a major public health issue in many countries. The risk for cardiovascular events has been shown to be high among patients with hypertensive conditions, particularly among those who have comorbidities such as diabetes, chronic kidney disease CKDmetabolic syndrome, cerebrovascular disorders, or organ dysfunction including heart disease. By clicking Subscribe, I agree to the Inesrt.
International Journal of Hypertension
Creatinine clearance was calculated using the Cockcroft-Gault formula. Eplerenone cannot be removed by hemodialysis. Eplerenoen diabetes was observed in It occurs because the heart is no longer able to maintain normal venouscapillary pressures, cardiac output, andor systemic blood pressure.
According to a survey by the Japanese Society of Nephrology [ 9 ], the frequency of CKD increases with age among Japanese men and women. Stopping Eplerenone following treatment for 8 to 24 weeks in six studies did not lead to adverse event rates in the week following withdrawal of Eplerenone greater than following placebo or active control withdrawal.
For inadequate blood pressure response, dosing may be increased to a maximum of 25 eplerrnone twice daily [See Dosage and Administration 2. These considerations may guide selection of therapy. Heart failure circulatory system merck veterinary manual.
Mineralocorticoid receptor antagonists MRAs have been shown to exert antihypertensive effects by binding to mineralocorticoid receptors MRs and blocking MR-dependent signal transduction. In a week study inserh hypertensive pediatric patients age 4 to 16 years treated with Eplerenone up to mg per day, doses that produced exposure similar to that in packge, Eplerenone did not lower blood pressure effectively. The finding that eplerenone gradually reduced BP over months is consistent with a previous inaert [ 9 ].
Pdf distinguishing the antihypertensive and electrolyte. For Patients Treated for Hypertension. Gynecomastia and abnormal vaginal bleeding were reported with Eplerenone but not with placebo.
Although the incidence of hyperkalemia tended to be higher among patients prescribed ACE inhibitors or ARBs concomitantly with eplerenone, it was considered within the scope of the package insert of Selara tablets. Third, because there were no exclusion criteria in this study, patients with severe conditions such as active malignancy were not excluded, which might have affected the safety and efficacy parameters.
Of the patients that were surveyed, it was confirmed that those included in the safety analysis had taken eplerenone at least once during the observation period. Patiromer, an oral potassium binder, was recently approved by the food and drug administration fda for treatment of chronic hyperkalemia but has drugdrug interactions that complicate dosing when taken with oral medications.
Eplerenone is cleared predominantly by cytochrome P CYP 3A4 metabolism, with an elimination half-life of 3 to 6 hours.